IKT
Inhibikase Therapeutics, Inc.1.6000
-0.0200-1.23%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
194.03MP/E (TTM)
3.40Basic EPS (TTM)
0.47Dividend Yield
0%Recent Filings
10-K
8-K
8-K
8-K
Launches $93.6M stock offering
Inhibikase Therapeutics launched a $93.6M public offering of 46M shares at $1.45 and pre-funded warrants to certain investors, expecting closure November 24, underwritten by Jefferies, BofA, and Cantor. Net proceeds could hit $107.7M if the 30-day overallotment option activates. Holders amended prior Series A-1 and B-1 warrants to back IKT-001's Phase 3 PAH trial push.
8-K
Phase 3 PAH trial launches Q1 2026
Inhibikase Therapeutics announced on November 20, 2025, plans to launch its adaptive Phase 3 IMPROVE-PAH study of IKT-001 in PAH during Q1 2026, skipping the prior Phase 2b after positive FDA feedback. Part A tests PVR reduction in 140 patients; Part B evaluates 6MWD in 346 patients, featuring 12-week dose titration for optimal tolerability. No sales made under terminated ATM prospectus. Execution accelerates.
APTOF
Aptose Biosciences. Inc.
1.60-0.04
CGTX
Cognition Therapeutics, Inc.
1.52-0.08
CYTK
Cytokinetics, Incorporated
62.02-0.14
GALT
Galectin Therapeutics Inc.
6.20-0.31
GANX
Gain Therapeutics, Inc.
3.86-0.09
IGC
IGC Pharma, Inc.
0.34+0.00
INBX
Inhibrx Biosciences, Inc.
81.57+5.36
INTI
Inhibitor Therapeutics Inc.
0.05-0.00
KTTA
Pasithea Therapeutics Corp.
1.14-0.02
VKTX
Viking Therapeutics, Inc.
35.72-0.43